The coronavirus pandemic (COVID-19) is actively spreading around the world, affecting 188 countries and territories. At the beginning of the fitness crisis, Italy was one of the worst affected countries. The country now ranks 18th on the list of countries by cases shown with a number of cases of 260,298 infections and more than 35,000 deaths.
Although the infection rate has slowed in the country, scientists have begun human trials of a vaccine against Coronavirus 2 of Severe Acute Respiratory Syndrome (SARS-CoV-2), the virus that causes COVID-19 disease.
The Lazzaro Spallanzani Institute in Rome, a hospital specializing in infectious diseases, will carry out trials with 90 volunteers in the coming weeks, joining an effort to expand an immune reaction to the virus.
Scientists hope the vaccine will trigger an immune reaction to fight the infection. Europe, one of the regions hardest hit by the pandemic, has seen a resurgence in cases. If the vaccine is effective, scientists hope the vaccine will be available. the public until mid-2021.
The vaccine, called GRAd-COV2, developed through ReiThera, an Italian biotechnology company, encodes the complex full-length protein SARS-CoV-2 and is based on a new replication-defective adenoviral gorilla (GRAd).
The generation of vaccines has generated a strong cellular and amusing immune reaction in preclinical studies and has been shown to be effective. Firstly, the vaccine is able to be tested in humans, which induce strong immune reactions based on pre-existing low levels. vector immunity in humans.
Other vaccines on adenoviral vectors of apes, such as adenoviral vectors of chimpanzee (ChAd), have been observed and evaluated in phase 1 and 2 clinical trials.
Adenovirial vectors of apes (Sad) have been widely used as agents of administration for genetic vaccine applicants who oppose a multitude of infectious diseases, such as respiratory syncytial virus (RSV) and Ebola virus, which ravaged West Africa in 2014.
“The new ape adenovirus Reithera (GRAd) belongs to the adenovirus C species, as it is the vector of vaccines of maximum potency. the other advertisements of maximum hardness, ” said the vaccine on the website.
The clinical trial, which began on August 24, will recruit 90 healthy volunteers from two age cohorts: the 18-55-year-old organization and the 65-85-year-old organization. Each organization will be divided into 3 test groups of 15 volunteers. , who will get one of the 3 expanding doses of the vaccine. All participants will be monitored and evaluated for more than 24 weeks.
The phase 1 trial of the vaccine is being carried out recently through the Lazzaro Spallanzani National Institute of Infectious Diseases under the sponsorship of ReiThera. The main objective of the trial is to see if the prospective vaccine is and well tolerated in humans and if the vaccine can induce immune responses, adding antibodies and T cells, unlike SARS-CoV-2.
If the first level of the trial is promising, a phase 2 and a larger foreign phase 3 will begin until the end of 2020 in countries where the pandemic is active and spreading.
“This study is the vital first step in the clinical progression of our new GRAd-COV2 vaccine as opposed to COVID-19. We are proud to adopt this trial in Italy, where the effect of COVID-19 was felt”, Stefano. Colloca, ReiThera’s CTO, said
“The cutting-edge science behind our technique is supported through many years of pioneering studies in adenoviral vector technologies with preclinical and clinical knowledge generated with a single-dose vaccine in other serious infectious diseases that demonstrate tough cellular and fun-loving immune responses. our generation platform has adapted to an epidemic scenario such as COVID-19 and has apparent production and compliance advantages, ”he added.
According to the World Health Organization (WHO), 139 vaccines are currently at the preclinical level of vaccine development. The fitness firm reports that a total of 30 vaccines are recently found in human trials, and of these, six candidate vaccines are at the final levels before being approved for public use.
The coronavirus pandemic has inflamed more than 23. 65 million people and has now killed more than 813,000 people.
Written by
Angela is a career and heart nurse, graduated by far (Cum Laude) from her Bachelor of Nursing degree from Baguio University, Philippines, is recently completing her master’s degree where she specialized in maternal and child nursing and has worked as a clinical instructor and educator at Baguio University School of Nursing.
Use one of the following to cite this article in your essay, job, or report:
apa
Laguipo, Angela. (2020, August 25). Italy begins human trials of a vaccine against COVID-19 News-Medical. Retrieved September 9, 2020 at https://www. news-medical. net/news/20200825/Italy-starts-human-trials-of- -COVID-19-vaccine. aspx.
Mla
Laguipo, Angela. ” Italy begins human trials of the COVID-19 vaccine. “News-Medical. 09 September 2020.
Chicago
Laguipo, Angela. ” Italy begins human trials of the COVID-19″ vaccine. News-Medical. https: //www. news-medical. net/news/2020825/Italy-starts-human-trials-of–COVID- 19-vacuna. aspx. (accessed 9 September 2020).
Harvard
Laguipo, Angela. 2020. Italy begins human trials of a vaccine opposed to COVID-19. News-Medical, viewed 07 September 2020, https://www. news-medical. net/news/20200825/Italy-starts-human-trials-of–COVID-19-vaccine. aspx.
News-Medical. net – An AZoNetwork site
Ownership and operation through AZoNetwork, © 2000-2020